Page 28 - Human Use News Today

  EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and...

Blueprint Medicines Corporation today announced the European Commission has approved AYVAKYT® (avapritinib) for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment. AYVAKYT is the first and only approved therapy for people living with ISM in Europe.

Sanofi SA (NASDAQ: SNY), DNDi, and the HAT-r-ACC consortium 

 - If approved by the European Commission, patients 12 years of age and older with severe sickle cell disease or transfusion-dependent beta thalassemia, for whom hematopoietic stem cell...

Sanofi SA SNY, DNDi, and the HAT-r-ACC consortium announce that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP)…

(RTTNews) - Takeda (TAK) announced the European Medicines Agencys Committee for Medicinal Products for Human Use has recommended the approval of ...

By Colin Kellaher Shares of Apellis Pharmaceuticals fell nearly 15% in premarket trading Thursday after the biopharmaceutical company warned of a likely...

Conference call today at 8:30 a.m. ET WALTHAM, Mass., Dec. 14, 2023 -- Apellis Pharmaceuticals, Inc. announced today an update on the ongoing review of its marketing authorization application for...

Apellis Pharmaceuticals Inc.’s stock tumbled 14% early Thursday, after the company said it’s been informed of a negative trend vote on the European marketing...

Shares of Apellis Pharmaceuticals, Inc. (APLS) are falling more than 21 percent Thursday morning after the company said it expects the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) to give a negative opinion on its marketing authorization application for Pegcetacoplan to treat geographic atrophy.